CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+17.65%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$1.6B
AUM Growth
+$1.6B
(+9.2%)
Cap. Flow
-$53M
Cap. Flow
% of AUM
-3.31%
Top 10 Holdings %
Top 10 Hldgs %
60.85%
Holding
38
New
3
Increased
13
Reduced
9
Closed
2
Top Buys
| 1 |
Alkermes
ALKS
|
$42.7M |
| 2 |
Nurix Therapeutics
NRIX
|
$37.1M |
| 3 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$23.4M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$21.6M |
| 5 |
Instil Bio
TIL
|
$10.2M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$56M |
| 2 |
Vaxcyte
PCVX
|
$44M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$30.1M |
| 4 |
Cogent Biosciences
COGT
|
$23.7M |
| 5 |
Immunovant
IMVT
|
$19.8M |
Sector Composition
| 1 | Healthcare | 99.53% |
| 2 | Financials | 0.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $167M | 10.46% | 3,350,000 +150,000 | +5% | +$7.49M |
|
2
Vera Therapeutics
VERA
$1.38B
| $109M | 6.84% | 2,475,000 | – | – |
|
3
Xenon Pharmaceuticals
XENE
$2.98B
| $106M | 6.64% | 2,700,000 -54,266 | -2% | -$2.14M |
|
|
4
Vaxcyte
PCVX
$4B
| $105M | 6.57% | 920,000 -385,000 | -30% | -$44M |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $105M | 6.54% | 4,100,000 +126,755 | +3% | +$3.24M |
|
|
6
Nuvalent
NUVL
$5.52B
| $96.2M | 6.01% | 940,000 -547,756 | -37% | -$56M |
|
|
7
Cogent Biosciences
COGT
$1.69B
| $81.4M | 5.09% | 7,539,930 -2,198,070 | -23% | -$23.7M |
|
|
8
Alkermes
ALKS
$4.78B
| $81.2M | 5.07% | 2,900,000 +1,525,000 | +111% | +$42.7M |
|
9
Soleno Therapeutics
SLNO
$3.6B
| $63.6M | 3.98% | 1,260,000 -165,000 | -12% | -$8.33M |
|
10
Spyre Therapeutics
SYRE
$996M
| $58.5M | 3.65% | 1,988,084 | – | – |
|
11
Viridian Therapeutics
VRDN
$1.5B
| $58M | 3.63% | 2,550,124 +22,092 | +0.9% | +$503K |
|
12
Celldex Therapeutics
CLDX
$1.47B
| $55M | 3.44% | 1,618,937 +193,937 | +14% | +$6.59M |
|
13
MindMed
MNMD
$676M
| $45.5M | 2.84% | 8,000,000 +854,112 | +12% | +$4.86M |
|
14
Perspective Therapeutics
CATX
$250M
| $44.7M | 2.79% | 3,350,000 -1,307,345 | -28% | -$17.5M |
|
|
15
Nurix Therapeutics
NRIX
$714M
| $37.1M | 2.32% | +1,650,000 | New | +$37.1M |
|
16
Pharvaris
PHVS
$1.39B
| $35.4M | 2.21% | 1,911,433 +101,258 | +6% | +$1.88M |
|
17
Kura Oncology
KURA
$686M
| $35.2M | 2.2% | 1,800,000 +206,650 | +13% | +$4.04M |
|
|
18
Rhythm Pharmaceuticals
RYTM
$6.85B
| $34.1M | 2.13% | 650,000 -575,000 | -47% | -$30.1M |
|
|
ORKA
19
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $33.6M | 2.1% | 1,369,714 +955,389 | +231% | +$23.4M |
|
20
Arvinas
ARVN
$568M
| $29.6M | 1.85% | 1,200,000 -684,361 | -36% | -$16.9M |
|
21
Celcuity
CELC
$2.17B
| $22.7M | 1.42% | 1,522,332 +58,227 | +4% | +$868K |
|
|
CNTA
22
Centessa Pharmaceuticals
CNTA
$2.25B
| $21.6M | 1.35% | +1,350,000 | New | +$21.6M |
|
23
Nkarta
NKTX
$151M
| $21.1M | 1.32% | 4,662,073 +511,039 | +12% | +$2.31M |
|
24
Oric Pharmaceuticals
ORIC
$994M
| $20.5M | 1.28% | 2,000,000 | – | – |
|
25
C4 Therapeutics
CCCC
$185M
| $19.4M | 1.21% | 3,410,384 | – | – |
|